LFMD vs OPRX

For growth investors, OptimizeRx Corporation (OPRX) is the stronger pick with 18.

8% revenue growth year-over-year, versus -8. 7% for LifeMD, Inc. (LFMD). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, LifeMD, Inc.

(LFMD) delivered a total return of -45. 8%, compared to -87. 3% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: LFMD returned +220. 7% versus OPRX's +110. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LifeMD, Inc.

(LFMD) is the lower-risk stock at 2. 12β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 7% more volatile than LFMD relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 27% for LifeMD, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), OptimizeRx Corporation (OPRX) is pulling ahead at 18.

8% versus -8. 7% for LifeMD, Inc. (LFMD). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 56. 6% for LifeMD, Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -3. 7% for LifeMD, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -4. 0% for LFMD. At the gross margin level — before operating expenses — LFMD leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OPRX: 156.

4% to $17. 00.

In this comparison, LFMD (1.

5% yield) pays a dividend. OPRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LifeMD, Inc.

(LFMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1. 5% yield, +220. 7% 10Y return). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LFMD: +220. 7%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LFMD is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. LFMD pays a dividend while OPRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.